Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.

Among patients with relapsing multiple sclerosis, 450 mg of ublituximab could be safely infused in 30 minutes at week 24.

The risk of developing MS and other demyelinating diseases is 3 times greater in individuals diagnosed with EBV-positive IM.

Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

The Alzheimer's Association revised the diagnostic criteria for Alzheimer disease (AD) and ADRD for clinicians in primary and specialty care.

Rates of genetic testing for autism and intellectual and development disorders were associated with race, gender, and insurance company.

There is an inverse bidirectional association between cancer and dementia, a relationship that holds across cancer and dementia subtypes.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

Women with epilepsy may have offspring with decreased bone metabolism and lower birth weight, according to a study.